L-Histidine resensitizes multidrug-resistant bacteria to carbapenems by inhibiting New Delhi metallo-β-lactamase activity
PLOS Pathogens · 26.10.2026 · 22 (10) · e1014728
DOI: 10.1371/journal.ppat.1014728 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, online erschienen am 26.10.2026. Verfasst von Yanqing Yin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, College of Veterinary Medicine, Yangzho…. Hauptthemen laut MEDLINE: beta-Lactamases, Carbapenems, Drug Resistance, Multiple, Bacterial, Histidine. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Plasmid-mediated New Delhi metallo-β-lactamase (NDM)-producing Gram-negative pathogens have severely undermined the clinical utility of carbapenems, the last-resort antibiotics for multidrug-resistant infections. Given the limited pipeline of novel antibiotics, there is an urgent need for more effective anti-infective strategies. Through untargeted metabolomics and functional screening, we find that L-histidine (L-His), a key downregulated metabolite in NDM-positive bacteria, remarkably restores carbapenem susceptibility. Mechanistically, L‑His acts through two complementary pathways: (i) direct competitive inhibition of NDM enzymatic activity via zinc chelation at the active site, and (ii) upregulation of the nickel ion transport gene cluster nikABCDE , which increases intracellular Ni 2+ accumulation and further suppresses NDM function through non‑competitive inhibition. Overexpression of nikA potentiates the bactericidal activity of meropenem, whereas deletion of nikAB attenuates the synergistic effect of L‑His and meropenem. In a murine peritonitis‑sepsis model, co‑administration of L‑His with meropenem significantly improves survival and reduces bacterial burden, with a favorable safety profile. Collectively, our findings reveal L‑His as a multi‑mechanistic metabolic adjuvant that combines direct enzyme inhibition with disruption of metal homeostasis, positioning it as a promising therapeutic strategy against NDM‑positive carbapenem‑resistant infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, College of Veterinary Medicine, Yangzhou University, Yangzhou, China.
- Joint International Research Laboratory of Agriculture and Agri-Product Safety, the Ministry of Education of China, Yangzhou University, Yangzhou, China.
- Institute of Comparative Medicine, Yangzhou University, Yangzhou, China.
ORCID-Profile: Yuan Liu
Zitieren
APA
Yin, Y., Hu, S., Fang, D., Huang, Y., Huang, M., Liu, S., Wang, Z., & Liu, Y. (2026). L-Histidine resensitizes multidrug-resistant bacteria to carbapenems by inhibiting New Delhi metallo-β-lactamase activity. PLOS Pathogens, 22(10), e1014728. https://doi.org/10.1371/journal.ppat.1014728
Vancouver
Yin Y, Hu S, Fang D, Huang Y, Huang M, Liu S, et al. L-Histidine resensitizes multidrug-resistant bacteria to carbapenems by inhibiting New Delhi metallo-β-lactamase activity. PLOS Pathogens. 2026;22(10):e1014728. doi:10.1371/journal.ppat.1014728
BibTeX
@article{Yin2026,
author = {Yin, Yanqing and Hu, Sulan and Fang, Dan and Huang, Yanhu and Huang, Miaomiao and Liu, Suhong and Wang, Zhiqiang and Liu, Yuan},
title = {L-Histidine resensitizes multidrug-resistant bacteria to carbapenems by inhibiting New Delhi metallo-β-lactamase activity},
journal = {PLOS Pathogens},
year = {2026},
volume = {22},
number = {10},
pages = {e1014728},
doi = {10.1371/journal.ppat.1014728}
}
EUVIMED